NNZ-2566 is a novel, small molecule being developed as a treatment for cognitive impairment in different CNS conditions, including Rett and Fragile-X syndrome, both of which are associated with moderate to severe neurodevelopmental disorder. In the current study we characterise the population pharmacokinetics of NNZ-2566 after administration of single and repeated ascending doses to healthy subjects. A meta-analytical approach was used to analyse pharmacokinetic data from 3 different studies, in which a total of 61 healthy subjects (median age: 23 years, range: 19 to 38) were treated with NNZ-2566. Doses of NNZ-2566 ranged from 6.0 to 100 mg/kg after oral administration and from 0.1 to 30 mg/kg after intravenous administration. A two-compartment model with first order absorption and elimination was found to best describe the pharmacokinetics of NNZ-2566. Interindividual variability was identified in clearance, absorption rate, central volume of distribution, peripheral volume of distribution and inter-compartmental clearance. Population predicted clearance and central volume of distribution were 10.35 L/h and 20.23 L, respectively. Dose proportionality was observed across the dose range evaluated in healthy subjects. No accumulation, metabolic inhibition or induction was observed during the course of treatment. In addition, oral bioavailability appeared to vary with food intake. The relatively short halflife of 1.4 h suggests the need for a twice or three times daily regimen to maintain relevant blood levels of NNZ-2566.
Introduction
Rett syndrome is one of the most common causes of mental retardation in females (Hagberg et al., 1985) . Rett syndrome was first described by Andreas Rett in 1966 (Rett, 1966 . It is a severe genetically determined neurological disorder in which individuals are intellectually handicapped and suffer a variety of psychiatric symptoms. Loss of function mutations in the MeCP2 gene is thought to be the primary cause (Amir et al., 1999; van Karnebeek et al., 2016) . The disorder is characterised by normal early growth followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizure and intellectual disability and many features of autism (Colvin et al., 2003; Weaving et al., 2005) . The annual mortality rate of 1.2% in Rett syndrome is higher than that of the general population (Kerr et al., 1997) , of which 26% of mortality is accounted for by sudden death. The cause of sudden death appears to be related to the presence of epilepsy or autonomic cardio-respiratory difficulties.
Unfortunately, there are no effective treatment options for these patients (Djukic et al., 2016; Percy, 2016) . Pharmacological and nonpharmacological interventions are symptomatic and supportive, with medication being used for breathing irregularities, cardiovascular issues, motor difficulties and seizures. Some children may require special equipment, including braces to stop scoliosis, splints to modify hand movements and dietary programs to maintain weight.
NNZ-2566 (trofinetide) is a novel, small molecule with the structure glycine-2-methylproline-glutamate and a molecular weight of 315.3 g/ mol. NNZ-2566 is an analogue of the N-terminal tripeptide of insulinlike growth factor 1, ), modified to enhance its systemic stability and increase its plasma half-life. Despite the differences in molecular weight, NNZ-2566 and IGF-1[1-3] are very similar structurally and in terms of biological activity. Pre-clinical data have shown that treatment with insulin-like growth factor 1 (IGF1) and its active peptide (1-3) IGF1 significantly ameliorates disease symptoms in a mouse model of the disease. In addition, both moieties cross the blood brain barrier, making it an ideal candidate for the treatment of neurodevelopmental disorders, such as Rett syndrome (Pini et al., 2014) .
From a physiological perspective, IGF-1 is released in response to the production of growth hormone, and deficiencies of IGF-1 result in a phenotype that overlaps with that of growth hormone deficiency. The effects of IGF-1 appear to be mediated by the IGF-1 receptor, where it acts as a stimulator of the Akt pathway (Vahdatpour et al., 2016) . In Table 1 Studies included in the population pharmacokinetic analysis of NNZ-2566.
Study description 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150 and 180 min post-start of infusion.
Neu-2566-HV-004: a phase I, double-blind, randomized, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566
Healthy subjects (female) 6 mg/kg i.v. bolus over 10 min 20 mg/kg i.v. bolus over 10 min 20 mg/kg i.v. bolus over 10 min followed by 1 mg/ kg/h for 72 h 20 mg/kg i.v. bolus over 10 min followed by 3 mg/ kg/h for 72 h 20 mg/kg i.v. bolus over 10 min followed by 6 mg/ kg/h for 72 h 10 min i.v. bolus followed by long infusion
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A phase I, double-blind, randomized, dose escalation study to assess the safety, tolerability, and pharmacokinetics of NNZ-2566 in healthy subjects, following oral administration Mecp2-null (Mecp2(-/y)) mice, which have low IGF-1 levels, systemic treatment with recombinant human IGF1 (rhIGF1) improves lifespan, locomotor activity, heart rate, respiration patterns, and social and anxiety behaviour (Castro et al., 2014) . Recently, Phase I studies have demonstrated the safety and tolerability of NNZ-2566 in healthy subjects. In these studies, blood samples have also been collected for the characterisation of the pharmacokinetics of NNZ-2566 after oral and intravenous administration. Here we aim to develop a population pharmacokinetic model to establish the linearity in absorption and disposition of the compound and explore the potential effect of demographic factors on the pharmacokinetics of NNZ-2566. The main justification for the use of a model-based metaanalytical approach is the availability of concentration vs. time data from different routes, treatment duration and regimens tested across various cohorts, which make it difficult to summarise the pharmacokinetic parameters of interest, such as AUC, Cmax, and C τ . Most importantly, the use of a parametric approach allows further evaluation and prediction of the systemic exposure in subsequent clinical trials in patients, for which a sparse blood sampling scheme is required. Our approach is also aimed at exploring other clinically relevant measures of exposure (e.g., cumulative exposure, steady-state concentration [Css] ), which may be relevant for the assessment of the pharmacokinetic-pharmacodynamic relationships of NNZ-2566.
Material and methods

Analysis populations
All of the studies included in this analysis were conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki, as embodied in the Australian National Statement on Ethical Conduct in Research Involving Humans and were conducted in accordance with the ICH Guideline for Good Clinical Practice (GCP). The clinical study protocols, amendments to the protocols, and versions of the subject informed consent forms (ICF) used in the studies were reviewed and approved by the Alfred Ethics and Research Committee; Alfred Research and Ethics Unit, Alfred Hospital, Commercial Road, Melbourne, VIC 3004, Australia.
The population pharmacokinetic analysis comprised data from three studies of single and multiple doses of NNZ-2566 in healthy subjects. NNZ-2566 doses ranged from 0.1 to 20 mg/kg in 10 min I.V. infusions and 6 mg/kg to 100 mg/kg by oral administration. In total, 61 healthy subjects who received the NNZ-2566, and from whom blood samples were collected, were considered evaluable for the purposes of this analysis. An overview of the design, dose, dosing regimen and sampling schedule used for the assessment of the pharmacokinetics in each study is presented in Table 1 .
Bioanalytical methods
Blood concentrations of NNZ-2566 were analysed by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/ MS). The calibration curves were constructed using the ratios of areas vs. concentration of NNZ-2566 (0.100 μg/mL-100 μg/mL in whole blood) showed linearity within the levels observed in the study. The limit of quantification in whole blood was 0.100 μg/mL.
Pharmacokinetic modelling
Population pharmacokinetic modelling and simulation was performed using a nonlinear mixed effects approach, as implemented in NONMEM version 7.3 (Beal et al., 2009 ). First, a base model (no covariates) was built. This was accomplished by first identifying the appropriate structural model parameters. The appropriate stochastic models of between-subject and inter-occasion variability were then integrated in a hierarchical manner. Selected covariates were identified using a stepwise forward inclusion backward deletion approach. Covariate effects were considered for the primary model parameters only (e.g., Ka, CL, V2). Biologically plausible factors identified prospectively to be tested in the covariate analysis included age, weight, route of administration, dose and food intake. R version 3.1.3 was used for data formatting and creation of tabular and graphical summaries (R. Core Team, 2015).
Stochastic model
Inter-individual variability (IIV) in the pharmacokinetic parameters was assumed to be log-normally distributed. Given subject i, the individual parameter value is given by:
where θ tv is the typical value in the population and η i is a random variable with a mean of zero and variance ω 2 . Residual variability was described with an exponential error model. Inter-occasion variability (IOV) was tested on absorption parameters, distribution volumes, and clearance (CL) and was included as follows:
where κ o represents occasion o, which is normally distributed with a mean of zero and variance ω 2 . Given the j th measurement of individual i the modelled value of the concentration (Y ij ) was given by:
where F ij is the predicted concentration and ε ij a random variable with a mean of zero and variance σ 2 . 
Covariate model
PK model building was performed using the FOCE-I estimation method. Covariate analysis was performed to explore potential sources of variability in the pharmacokinetics of NNZ-2566. Selected covariates were added to the base model in a stepwise fashion. Initially, each factor was included individually into the base model if a reduction in the objective function value (OFV) of ≥ 3.84 was observed. The difference in -2Log likelihood between the base and the full model is approximately χ 2 distributed, with degrees of freedom equal to the difference in number of parameters between the two hierarchical models (p < 0.05). The following covariate models were investigated:
-Linear model:
-Exponential model:
where θ cov is the covariate specific effect, COV i the individual covariate value and COV med the population median. During the final modelling steps, only the factors (inter-individual variability, covariates) which resulted in OFV reduction of ≥ 7.88 (p < 0.005) have been kept in the model. Model performance was assessed by numerical, graphical and statistical procedures, including visual predictive checks, bootstrapping, normalised prediction discrepancy error (NPDE) and mirror plots. Final parameter estimates were summarised along with their confidence intervals when appropriate.
Visual predictive checks (VPC) were used to evaluate the adequacy of the final model parameter estimates, including the effects of statistically significant covariates, to produce simulated data that were similar to the observed data. In the VPC, 1000 replicates of the original data set are simulated and a 90% prediction interval is computed based on the simulated data sets. The observed concentration vs. time data is then overlaid on the prediction interval to visually assess the concordance between simulated and observed data.
Bootstrapping was performed to identify bias, stability, and accuracy of the parameter estimates and generate standard errors and confidence intervals on the parameter estimates. For the bootstrapping, PsN was used to generate 1000 new data sets by sampling individuals with replacement from the original data set and then fitting the model to each new data set. Further evaluation of the variance-covariance structure and overall random effects in the model was performed using mirror plots and NPDE diagnostics. To generate mirror plots, the population PK parameters estimates were used to simulate blood concentrations in patients with similar demographic characteristics, dosing regimens, and sampling scheme as those in the original clinical studies. Mirror plots of individual predicted versus observed concentration were created to evaluate the degree of similarity between the original fit and the pattern obtained from the simulated data sets. Finally, NPDE was estimated. Plots to evaluate whether the discrepancies between observed and predicted values were normally distributed included a quantilequantile (QQ) plots of NPDE vs. the expected standard normal distribution, a histogram of NPDE along with the density of the standard normal distribution, a scatter plot of NPDE vs. observed values, and a scatter plot of NPDE vs. predicted values.
Secondary pharmacokinetic parameters
Secondary pharmacokinetic parameters were calculated based on individual predicted concentrations simulated every 0.1 h. AUC was calculated by using the trapezoidal rule. Cmax was the maximum predicted concentration observed per individual, whereas the half-life was 
S.P. Oosterholt et al. European Journal of Pharmaceutical Sciences 109 (2017) S98-S107
S102
calculated by dividing ln(2) by the elimination rate constant.
Results
The age of subjects across all studies included in the current analysis ranged from 19 to 38 years, whereas weight ranged between 53.4 and 95 kg. Weight, height and BMI were all positively correlated with one another. A summary of the demographic characteristics and studied covariates is presented by study and for the overall population in Table 2 . The majority of subjects were female (69%). Neu-2566-HV-001 included only male subjects (n = 20) while Neu-2566-HV-004 included only female subjects (n = 29).
In total, 1435 samples were analysed. Of the total number of samples available, 20 were excluded as they had concentrations below the limit of detection. In addition, data from 6 individuals receiving doses of 6 mg/kg doses of NNZ-2566 had to be excluded from the analysis due to unexplained variability in drug levels, which seemed to increase throughout the sampling interval. A sensitivity analysis showed that the exclusion of these individuals had no further implications for model development and parameter estimation. Of all the population parameter estimates only the absorption rate constant deviated > 10%, the IIV parameters Ka, V2 and CL were respectively 3.5, 2.5 and 1.5 times higher when the 6 mg/kg individuals were included in the analysis. The blood NNZ-2566 concentration-time profiles were consistent across studies and regimens (Fig. 1). 
Modelling results
The pharmacokinetics of NNZ-2566 following intravenous administration to healthy subjects was best described by a 2-compartment model with first order elimination (Fig. 2) . Oral administration of NNZ-2566 was characterised by two parameters (F1 AM , F1 PM ) describing diurnal variation in bioavailability, with lower systemic exposure observed after the afternoon/evening doses, most likely reflecting the impact food effect. IIV was identified for CL, V2 (Table 3) . No covariate effects were found on any of the model parameters. The residual error was described using an exponential error model.
All parameters were well estimated without significant correlations between parameters and with good precision (% relative standard error (RSE) < 16%). The IIV effects were also estimated with reasonable precision (%RSE < 11%). The diagnostic plots (Fig. 3) showed that the model adequately described the data and produced unbiased population and individual predictions. No trend or bias was noted between the conditional weighted residuals and predicted concentration or covariate (body weight). Inter-individual random effects were close to normally distributed and data were found to be uncorrelated.
The non-parametric bootstrap estimates of the primary PK parameters were similar to the NONMEM estimates (Table 3 ). In addition, the mirror plots showed that the final population PK model accurately replicated the data of healthy subjects across the different studies (Fig. 4) .
From the VPC plots (Fig. 5) , it seems that the median concentration is slightly overestimated. Given that the IIV for CL and V2 is < 10%, such an overestimation may be explained by the estimated residual variability, The NPDE plots (Fig. 1S) did not reveal any additional bias for any of the dose levels included in the analysis (See supplemental material).
Estimates of the secondary pharmacokinetic parameters (Table 4 ) seem consistent across studies and dose levels, indicating linear pharmacokinetics and dose proportionality. However, results from study HV-005 showed a slightly lower normalised AUC.
Discussion
Our analysis has allowed the characterisation of the pharmacokinetic properties of NNZ-2566, a synthetic analogue of a naturally occurring neurotrophic peptide derived from insulin-like growth factor-1 (IGF-1), in healthy subjects (Bickerdike et al., 2009; Tropea et al., 2009) . Created as a non-proteinogenic analogue to IGF-1[1-3] to increase its protease resistance, NNZ-2566 has shown an increase in plasma half-life (49 min) in rats compared to its naturally occurring tripeptide glypromate (4.95 min) (Batchelor et al., 2003; Bickerdike et al., 2009) . The pharmacokinetic profiles observed in healthy subjects show an even higher half-life of 1.4 h, a significant improvement considering its route of administration.
In addition, our results contrasts with published data on mecasermin, a recombinant IGF-1, which has been recently evaluated in Rett syndrome patients (Pini et al., 2014) . Mecasermin was found to have a considerably longer half-life (between 12.9 and 21 h) (CamachoHubner et al., 2006; Khwaja et al., 2014) than NNZ-2566, but it requires intravenous administration. NNZ-2566 has a clear therapeutic advantage in that it can be delivered orally. In addition, IGF-1 is believed to have limited blood-brain-barrier permeability (EMA, 2007) , unlike the IGF-1 tripeptide (Tropea et al., 2009 ) on which NNZ-2566 is based.
NNZ-2566 showed linear pharmacokinetics across the dose range evaluated in the clinical trials included in this analysis. In fact, zeroorder processes did not explain some of the deviation in model predictions observed for some of the samples within the high concentration range. From a pharmacokinetic perspective, there was no accumulation, metabolic inhibition, or induction observed during treatment. Moreover, good oral bioavailability and low inter-individual variability were observed after oral administration. The population estimate for the volume of distribution at steady-state (i.e., sum of the volumes of distribution for the central and peripheral compartments) was 61.7 L, i.e. larger than total body water. This indicates that NNZ-2566 does distribute into fat tissue and that treatment effects observed in preclinical species may indeed result from drug distribution into the brain. The lack of identifiable covariates effects such as weight on the pharmacokinetics of NNZ-2566 is not unexpected, as such an effect is usually observed in groups with more widely ranging demographic characteristics (Jusko and Chiang, 1982; Kersting et al., 2012; Piana et al., 2014 ) as compared to a relatively homogenous group of healthy subjects.
The availability of a population pharmacokinetic model will facilitate the evaluation of drug exposure in future clinical trials in patients suffering from neurodevelopmental disorders. In these patients, sparse sampling schemes will have to be used, with only a few samples taken per patient. Estimating secondary parameters such as Cmax, AUC and half-life or even developing a comprehensive pharmacokinetic model will be difficult. In addition to addressing the limitations of sparse sampling, we envisage the possibility of applying Bayesian priors to facilitate the estimation of inter-individual variability on key pharmacokinetic parameters such as clearance (Dansirikul et al., 2006; Kashuba et al., 1996) . This will allow the evaluation of exposure-effect relationships, taking into account the inter-individual variability in pharmacokinetics. Moreover, our approach provides the basis for study design optimisation. Sampling schemes can be far more informative if sampling times and sampling frequency are defined taking into account ED-optimality concepts and relevant sources of variability (Bellanti et al., 2016) .
Conclusions
In summary, we have shown that the population pharmacokinetics of NNZ-2566 can be best described by a two-compartment model with first order oral absorption and first order elimination. Administration of different doses and dosing regimens of NNZ-2566 to healthy subjects yielded dose proportional changes in exposure. Despite the homogeneous cohort of healthy subjects, inter-individual variability and inter-occasion variability were identified for CL, V, and Ka. Estimates of the volume of distribution suggest that the compound distributes into Table 4 Overview of secondary pharmacokinetic parameters.
Numbers reported are the geometric mean and 95% confidence interval. AUC is the area under the curve for the total study. Normalized AUC is the AUC divided by the total drug taken.
tissue, beyond total body water, making it a suitable candidate for the treatment of neurodevelopmental disorders. Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.ejps.2017.05.032.
